Finance

Lists
6919:TPE
Caliway Biopharmaceuticals Co Ltd
NT$79,90
+1,01%
(+0,80) 1D
2 Okt., 13:30:06 GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 6919...
Open
NT$79,10
High
NT$80,40
Low
NT$78,50
Mkt. cap
124,42 mjd
Avg. vol.
9,11 m
Volume
3,64 m
52-wk high
NT$195,00
52-wk low
NT$75,10
EPS
-NT$0,17
Open
NT$79,10
High
NT$80,40
Low
NT$78,50
Mkt. cap
124,42 mjd
Avg. vol.
9,11 m
Volume
3,64 m
52-wk high
NT$195,00
52-wk low
NT$75,10
EPS
-NT$0,17
News stories
From web sources and news partners
About Caliway Biopharmaceuticals Co Ltd
CEO-
Employees-
Founded2012
Headquarters-
SectorPharmaceutical industry
Websitecaliwaybiopharma.com
Last report
11 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (TWD)
-NT$0,14 / NT$2,93
-104,78%miss
Revenue / Est. (TWD)
3,57 m / 6,01 mjd
-99,94%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
13,42 m
12,41 m
2,00 k
3,57 m
Cost of goods sold
4,09 m
3,40 m
1,00 k
1,24 m
Cost of revenue
4,09 m
3,40 m
1,00 k
1,24 m
Research and development expenses
244,51 m
112,62 m
212,41 m
210,66 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-33,70 m
17,06 m
33,42 m
54,75 m
Operating expense
210,81 m
129,69 m
245,83 m
265,41 m
Total operating expenses
214,89 m
133,09 m
245,83 m
266,65 m
Operating income
-201,48 m
-120,68 m
-245,83 m
-263,08 m
Other non operating income
-280,00 k
9,00 k
-4,00 k
-2,00 k
EBT including unusual items
-7,73 m
80,19 m
-107,75 m
-222,52 m
EBT excluding unusual items
-7,73 m
80,19 m
-107,75 m
-222,52 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7,73 m
80,19 m
-107,75 m
-222,52 m
Net profit margin
-57,62%
646,17%
-5 387 700,00%
-6 239,93%
Earnings per share
-0,01
0,05
-0,07
-0,14
Interest and investment income
59,73 m
85,42 m
78,51 m
82,27 m
Interest expense
-34,00 k
-22,00 k
-11,00 k
-329,00 k
Net interest expenses
59,70 m
85,40 m
78,50 m
81,94 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-195,81 m
-114,79 m
-239,81 m
-258,15 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme